{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:57:04Z","timestamp":1774969024623,"version":"3.50.1"},"publisher-location":"Singapore","reference-count":138,"publisher":"Springer Singapore","isbn-type":[{"value":"9789813297166","type":"print"},{"value":"9789813297173","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-981-32-9717-3_8","type":"book-chapter","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T07:03:54Z","timestamp":1574406234000},"page":"213-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stimulatory and Inhibitory Co-signals in Autoimmunity"],"prefix":"10.1007","author":[{"given":"Taku","family":"Okazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il-mi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,23]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.4049\/jimmunol.1601135","volume":"197","author":"AB Adams","year":"2016","unstructured":"Adams AB, Ford ML, Larsen CP (2016) Costimulation blockade in autoimmunity and transplantation: the CD28 pathway. J Immunol 197:2045\u20132050","journal-title":"J Immunol"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJ Ansari","year":"2003","unstructured":"Ansari MJ et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198:63\u201369","journal-title":"J Exp Med"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.4049\/jimmunol.0802610","volume":"183","author":"M Araki","year":"2009","unstructured":"Araki M et al (2009) Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol 183:5146\u20135157","journal-title":"J Immunol"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4049\/jimmunol.163.3.1128","volume":"163","author":"MF Bachmann","year":"1999","unstructured":"Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M (1999) Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 163:1128\u20131131","journal-title":"J Immunol"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124:1111\u20131121","journal-title":"Cancer"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/art.24227","volume":"60","author":"GK Bertsias","year":"2009","unstructured":"Bertsias GK et al (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1\/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 60:207\u2013218","journal-title":"Arthritis Rheum"},{"key":"8_CR7","first-page":"e57","volume":"4","author":"J Boike","year":"2017","unstructured":"Boike J, Dejulio T (2017) Severe esophagitis and gastritis from nivolumab therapy ACG case. Rep J 4:e57","journal-title":"Rep J"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175","journal-title":"J Clin Oncol"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell co-receptors for cancer therapy. Immunity 44:1069\u20131078","journal-title":"Immunity"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43\u201350","journal-title":"Ann Rheum Dis"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jneuroim.2006.10.006","volume":"182","author":"LL Carter","year":"2007","unstructured":"Carter LL et al (2007) PD-1\/PD-L1, but not PD-1\/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 182:124\u2013134","journal-title":"J Neuroimmunol"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2005.05.5434","volume":"24","author":"TY Cheng","year":"2006","unstructured":"Cheng TY et al (2006) Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24:3483\u20133489","journal-title":"J Clin Oncol"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","volume":"17","author":"AV Collins","year":"2002","unstructured":"Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201\u2013210","journal-title":"Immunity"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2350-8-71","volume":"8","author":"JD Cooper","year":"2007","unstructured":"Cooper JD et al (2007) The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med Genet 8:71","journal-title":"BMC Med Genet"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24:T331\u2013T347","journal-title":"Endocr Relat Cancer"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562\u2013567","journal-title":"Nat Med"},{"key":"8_CR17","first-page":"562","volume":"9","author":"M Cutolo","year":"2013","unstructured":"Cutolo M, Nadler SG (2013) Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritisx. Nat Med 9:562\u2013567","journal-title":"Nat Med"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF Maleissye de","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:296\u2013297","journal-title":"N Engl J Med"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1167\/iovs.17-22195","volume":"58","author":"J Deng","year":"2017","unstructured":"Deng J et\u00a0al (2017) Association of a PDCD1 polymorphism with sympathetic ophthalmia in Han Chinese. Invest Ophthalmol Vis Sci 58:4218\u20134222","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800","journal-title":"Nat Med"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1074-7613(04)00050-0","volume":"20","author":"H Dong","year":"2004","unstructured":"Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L (2004) B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20:327\u2013336","journal-title":"Immunity"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cancergencyto.2005.07.020","volume":"165","author":"N Erfani","year":"2006","unstructured":"Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165:114\u2013120","journal-title":"Cancer Genet Cytogenet"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino MC et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19:521\u2013536","journal-title":"Lancet Oncol"},{"key":"8_CR24","first-page":"127","volume":"8","author":"A Ghaderi","year":"2011","unstructured":"Ghaderi A (2011) CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol 8:127\u2013149","journal-title":"Iran J Immunol"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.106.635664","volume":"114","author":"S Goser","year":"2006","unstructured":"Goser S et al (2006) Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114:1693\u20131702","journal-title":"Circulation"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ajm.AJM_127_17","volume":"8","author":"A Haikal","year":"2018","unstructured":"Haikal A, Borba E, Khaja T, Doolittle G, Schmidt P (2018) Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. Avicenna J Med 8:34\u201336","journal-title":"Avicenna J Med"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1002\/eji.201040690","volume":"40","author":"KM Hamel","year":"2010","unstructured":"Hamel KM, Cao Y, Wang Y, Rodeghero R, Kobezda T, Chen L, Finnegan A (2010) B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. Eur J Immunol 40:3117\u20133127","journal-title":"Eur J Immunol"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1530\/EJE-07-0649","volume":"158","author":"M Hayashi","year":"2008","unstructured":"Hayashi M, Kouki T, Takasu N, Sunagawa S, Komiya I (2008) Association of an A\/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves\u2019 disease in Japanese patients. Eur J Endocrinol 158:817\u2013822","journal-title":"Eur J Endocrinol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.humimm.2016.04.018","volume":"77","author":"MM Hegab","year":"2016","unstructured":"Hegab MM et al (2016) CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians. Hum Immunol 77:522\u2013526","journal-title":"Hum Immunol"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.humimm.2010.05.023","volume":"71","author":"L Hu","year":"2010","unstructured":"Hu L et al (2010) CTLA-4 gene polymorphism +49 A\/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 71:888\u2013891","journal-title":"Hum Immunol"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-011-1440-3","volume":"129","author":"Z Hua","year":"2011","unstructured":"Hua Z et al (2011) PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat 129:195\u2013201","journal-title":"Breast Cancer Res Treat"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ker211","volume":"50","author":"CH Huang","year":"2011","unstructured":"Huang CH et al (2011) Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology (Oxford) 50:1809\u20131813","journal-title":"Rheumatology (Oxford)"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2337\/dc15-0401","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55\u2013e57","journal-title":"Diabetes Care"},{"issue":"6332","key":"8_CR35","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"Enfu Hui","year":"2017","unstructured":"Hui E et al. (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition Science 355:1428-1433","journal-title":"Science"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","volume":"99","author":"K Ikeuchi","year":"2016","unstructured":"Ikeuchi K, Okuma Y, Tabata T (2016) Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer 99:148\u2013150","journal-title":"Lung Cancer"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ni.1835","volume":"11","author":"W Ise","year":"2010","unstructured":"Ise W et al (2010) CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 11:129\u2013135","journal-title":"Nat Immunol"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 11:3887\u20133895","journal-title":"Embo J"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00439-009-0781-z","volume":"127","author":"Y Ishizaki","year":"2010","unstructured":"Ishizaki Y et al (2010) PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis. Hum Genet 127:411\u2013419","journal-title":"Hum Genet"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293\u201312297","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6:230ra245","journal-title":"Sci Transl Med"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/intimm\/dxp020","volume":"21","author":"F Jiang","year":"2009","unstructured":"Jiang F et al (2009) Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1\u2212\/\u2212 mice. Int Immunol 21:499\u2013509","journal-title":"Int Immunol"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471","journal-title":"Lancet"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bjh.15085","volume":"180","author":"T Kasamatsu","year":"2018","unstructured":"Kasamatsu T et al (2018) PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol 180:705\u2013714","journal-title":"Br J Haematol"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K et al (2016) Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature 534:402\u2013406","journal-title":"Nature"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL et al (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after >\/=1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6:7","journal-title":"J Immunother Cancer"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME et al (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:883\u2013895","journal-title":"J Exp Med"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","volume":"135","author":"M Kido","year":"2008","unstructured":"Kido M et al (2008) Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 135:1333\u20131343","journal-title":"Gastroenterology"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","volume":"113","author":"K Klocke","year":"2016","unstructured":"Klocke K, Sakaguchi S, Holmdahl R, Wing K (2016) Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A 113:E2383\u2013E2392","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907\u20131915","journal-title":"N Engl J Med"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","volume":"345","author":"HS Kuehn","year":"2014","unstructured":"Kuehn HS et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345:1623\u20131627","journal-title":"Science"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J et\u00a0al (2017) Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22:709\u2013718","journal-title":"Oncologist"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"10691","DOI":"10.1073\/pnas.0307252101","volume":"101","author":"YE Latchman","year":"2004","unstructured":"Latchman YE et al (2004) PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 101:10691\u201310696","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/eji.201746923","volume":"47","author":"L Laurent","year":"2017","unstructured":"Laurent L et al (2017) Prevention of lupus nephritis development in NZB\/NZW mice by selective blockade of CD28. Eur J Immunol 47:1368\u20131376","journal-title":"Eur J Immunol"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734\u20131736","journal-title":"Science"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1074-7613(00)80323-4","volume":"5","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow DJ et al (1996) CD28\/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285\u2013293","journal-title":"Immunity"},{"key":"8_CR57","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.163.4.2322","volume":"163","author":"B Liang","year":"1999","unstructured":"Liang B, Gee RJ, Kashgarian MJ, Sharpe AH, Mamula MJ (1999) B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1\/B7.2 or in the presence of anti-b7.1\/B7.2 blocking antibodies. J Immunol 163:2322\u20132329","journal-title":"J Immunol"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu J et\u00a0al (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A 112:6682\u20136687","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 181:2513\u20132521","journal-title":"J Immunol"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"12204","DOI":"10.1073\/pnas.200348397","volume":"97","author":"F Luhder","year":"2000","unstructured":"Luhder F, Chambers C, Allison JP, Benoist C, Mathis D (2000) Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A 97:12204\u201312209","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","volume":"19","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, Okazaki T (2018) LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol 19:1415\u20131426","journal-title":"Nat Immunol"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.4049\/jimmunol.164.10.5319","volume":"164","author":"EL Masteller","year":"2000","unstructured":"Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319\u20135327","journal-title":"J Immunol"},{"key":"8_CR64","first-page":"386","volume":"15","author":"Q Meng","year":"2009","unstructured":"Meng Q, Liu X, Yang P, Hou S, Du L, Zhou H, Kijlstra A (2009) PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis 15:386\u2013392","journal-title":"Mol Vis"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.4049\/jimmunol.179.11.7466","volume":"179","author":"J Menke","year":"2007","unstructured":"Menke J et\u00a0al (2007) Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol 179:7466\u20137477","journal-title":"J Immunol"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"issue":"12","key":"8_CR67","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1210\/jc.2009-1404","volume":"94","author":"Anna L. Mitchell","year":"2009","unstructured":"Mitchell AL et al. (2009) Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison\u2019s disease and Graves\u2019 disease susceptibility J Clin Endocrinol Metab 94:5139-5145","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"8_CR137","doi-asserted-by":"crossref","unstructured":"Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki I-m, Okazaki T (2019) PD-1 primarily targets TCR signal in the inhibition of functional T cell activation. Front Immunol 10:630. https:\/\/doi.org\/10.3389\/fimmu.2019.00630 . eCollection 2019","DOI":"10.3389\/fimmu.2019.00630"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.gene.2012.07.059","volume":"508","author":"Z Mojtahedi","year":"2012","unstructured":"Mojtahedi Z, Mohmedi M, Rahimifar S, Erfani N, Hosseini SV, Ghaderi A (2012) Programmed death-1 gene polymorphism (PD-1.5 C\/T) is associated with colon cancer. Gene 508:229\u2013232","journal-title":"Gene"},{"key":"8_CR69","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J et\u00a0al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391","journal-title":"Ann Oncol"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34\u201347","journal-title":"Nat Rev Immunol"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/eji.1830240602","volume":"24","author":"K Nishikawa","year":"1994","unstructured":"Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G (1994) Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 24:1249\u20131254","journal-title":"Eur J Immunol"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141\u2013151","journal-title":"Immunity"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319\u2013322","journal-title":"Science"},{"key":"8_CR138","doi-asserted-by":"publisher","first-page":"102296","DOI":"10.1016\/j.jaut.2019.06.007","volume":"105","author":"Hikari Okamura","year":"2019","unstructured":"Okamura H, Okazaki I-m, Shimizu K, Maruhashi T, Sugiura D, Mizuno R, Okazaki T (2019) PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions. J Autoimmun:102296. https:\/\/doi.org\/10.1016\/j.jaut.2019.06.007 . [Epub ahead of print]","journal-title":"Journal of Autoimmunity"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19:813\u2013824","journal-title":"Int Immunol"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98:13866\u201313871","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477\u20131483","journal-title":"Nat Med"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1084\/jem.20051984","volume":"202","author":"T Okazaki","year":"2005","unstructured":"Okazaki T, Otaka Y, Wang J, Hiai H, Takai T, Ravetch JV, Honjo T (2005) Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB\/c-Fcgr2b\u2212\/-Pdcd1\u2212\/\u2212 mice. J Exp Med 202:1643\u20131648","journal-title":"J Exp Med"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki T et al (2011) PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 208:395\u2013407","journal-title":"J Exp Med"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212\u20131218","journal-title":"Nat Immunol"},{"key":"8_CR80","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.4049\/jimmunol.163.5.2634","volume":"163","author":"MA Oosterwegel","year":"1999","unstructured":"Oosterwegel MA, Mandelbrot DA, Boyd SD, Lorsbach RB, Jarrett DY, Abbas AK, Sharpe AH (1999) The role of CTLA-4 in regulating Th2 differentiation. J Immunol 163:2634\u20132639","journal-title":"J Immunol"},{"key":"8_CR81","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543\u20139553","journal-title":"Mol Cell Biol"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1084\/jem.20141030","volume":"212","author":"AM Paterson","year":"2015","unstructured":"Paterson AM et al (2015) Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med 212:1603\u20131621","journal-title":"J Exp Med"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jneuroim.2017.02.006","volume":"305","author":"E Pawlak-Adamska","year":"2017","unstructured":"Pawlak-Adamska E et al (2017) PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. J Neuroimmunol 305:115\u2013127","journal-title":"J Neuroimmunol"},{"key":"8_CR84","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.4049\/jimmunol.154.3.1481","volume":"154","author":"PJ Perrin","year":"1995","unstructured":"Perrin PJ et al (1995) Role of B7:CD28\/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 154:1481\u20131490","journal-title":"J Immunol"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372\u20138377","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/dmrr.2552","volume":"30","author":"C Pizarro","year":"2014","unstructured":"Pizarro C, Garcia-Diaz DF, Codner E, Salas-Perez F, Carrasco E, Perez-Bravo F (2014) PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev 30:761\u2013766","journal-title":"Diabetes Metab Res Rev"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng1020","volume":"32","author":"L Prokunina","year":"2002","unstructured":"Prokunina L et al (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666\u2013669","journal-title":"Nat Genet"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/db09-1135","volume":"59","author":"T Rajasalu","year":"2010","unstructured":"Rajasalu T et al (2010) Deficiency in B7-H1 (PD-L1)\/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 59:1966\u20131973","journal-title":"Diabetes"},{"key":"8_CR89","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","volume":"62","author":"AP Raptopoulou","year":"2010","unstructured":"Raptopoulou AP et al (2010) The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 62:1870\u20131880","journal-title":"Arthritis Rheum"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","volume":"12","author":"J Romo-Tena","year":"2013","unstructured":"Romo-Tena J, Gomez-Martin D, Alcocer-Varela J (2013) CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 12:1171\u20131176","journal-title":"Autoimmun Rev"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.20022119","volume":"198","author":"AD Salama","year":"2003","unstructured":"Salama AD et al (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198:71\u201378","journal-title":"J Exp Med"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","volume":"12","author":"B Salomon","year":"2000","unstructured":"Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA (2000) B7\/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431\u2013440","journal-title":"Immunity"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1084\/jem.194.5.677","volume":"194","author":"B Salomon","year":"2001","unstructured":"Salomon B et al (2001) Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 194:677\u2013684","journal-title":"J Exp Med"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","volume":"44","author":"FA Schildberg","year":"2016","unstructured":"Schildberg FA, Klein SR, Freeman GJ, Sharpe AH (2016) Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44:955\u2013972","journal-title":"Immunity"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D et al (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20:1410\u20131416","journal-title":"Nat Med"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1126\/science.7688139","volume":"261","author":"A Shahinian","year":"1993","unstructured":"Shahinian A et al (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609\u2013612","journal-title":"Science"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eucr.2017.12.006","volume":"17","author":"K Shimatani","year":"2018","unstructured":"Shimatani K, Yoshimoto T, Doi Y, Sonoda T, Yamamoto S, Kanematsu A (2018) Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor. Urol Case Rep 17:97\u201399","journal-title":"Urol Case Rep"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4049\/jimmunol.1201362","volume":"190","author":"M Stumpf","year":"2013","unstructured":"Stumpf M, Zhou X, Bluestone JA (2013) The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol 190:961\u2013969","journal-title":"J Immunol"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.4049\/jimmunol.1300470","volume":"191","author":"SJ Suchard","year":"2013","unstructured":"Suchard SJ et al (2013) A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J Immunol 191:4599\u20134610","journal-title":"J Immunol"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/srep00317","volume":"2","author":"Y Sugino","year":"2012","unstructured":"Sugino Y et al (2012) BALB\/c-Fcgr2bPdcd1 mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis. Sci Rep 2:317","journal-title":"Sci Rep"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/eji.201343967","volume":"44","author":"P Tabares","year":"2014","unstructured":"Tabares P et al (2014) Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412\/TAB08. Eur J Immunol 44:1225\u20131236","journal-title":"Eur J Immunol"},{"key":"8_CR103","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4049\/jimmunol.163.6.3153","volume":"163","author":"Y Tada","year":"1999","unstructured":"Tada Y et al (1999) Role of the costimulatory molecule CD28 in the development of lupus in MRL\/lpr mice. J Immunol 163:3153\u20133159","journal-title":"J Immunol"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/eji.200324746","volume":"35","author":"S Takahashi","year":"2005","unstructured":"Takahashi S et al (2005) In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur J Immunol 35:399\u2013407","journal-title":"Eur J Immunol"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eplepsyres.2013.09.004","volume":"107","author":"Y Takahashi","year":"2013","unstructured":"Takahashi Y et al (2013) Genetic variations of immunoregulatory genes associated with Rasmussen syndrome. Epilepsy Res 107:238\u2013243","journal-title":"Epilepsy Res"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clindermatol.2016.05.021","volume":"35","author":"S Tanasilovic","year":"2017","unstructured":"Tanasilovic S, Popadic S, Medenica L, Popadic D (2017) Pemphigus vulgaris and pemphigus foliaceus determined by CD86 and CTLA4 polymorphisms. Clin Dermatol 35:236\u2013241","journal-title":"Clin Dermatol"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.4049\/jimmunol.171.7.3348","volume":"171","author":"Q Tang","year":"2003","unstructured":"Tang Q et al (2003) Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171:3348\u20133352","journal-title":"J Immunol"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876\u20134884","journal-title":"J Immunol"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.4049\/jimmunol.169.4.1852","volume":"169","author":"EA Tivol","year":"2002","unstructured":"Tivol EA, Gorski J (2002) Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 169:1852\u20131858","journal-title":"J Immunol"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541\u2013547","journal-title":"Immunity"},{"key":"8_CR111","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tjarnlund","year":"2018","unstructured":"Tjarnlund A et al (2018) Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis 77:55\u201362","journal-title":"Ann Rheum Dis"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"8_CR113","first-page":"45","volume":"34","author":"D Tyrsin","year":"2016","unstructured":"Tyrsin D, Chuvpilo S, Matskevich A, Nemenov D, Romer PS, Tabares P, Hunig T (2016) From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:45\u201348","journal-title":"Clin Exp Rheumatol"},{"key":"8_CR114","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506\u2013511","journal-title":"Nature"},{"key":"8_CR115","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G et al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2:e000247","journal-title":"ESMO Open"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1074-7613(04)00110-4","volume":"20","author":"L Vijayakrishnan","year":"2004","unstructured":"Vijayakrishnan L et al (2004) An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20:563\u2013575","journal-title":"Immunity"},{"key":"8_CR117","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F et al (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374:333\u2013343","journal-title":"N Engl J Med"},{"key":"8_CR118","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2015.09.004","volume":"288","author":"M Wagner","year":"2015","unstructured":"Wagner M et al (2015) Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset. J Neuroimmunol 288:79\u201386","journal-title":"J Neuroimmunol"},{"key":"8_CR119","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","volume":"36","author":"LS Walker","year":"2015","unstructured":"Walker LS, Sansom DM (2015) Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 36:63\u201370","journal-title":"Trends Immunol"},{"key":"8_CR120","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T (2005) Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 102:11823\u201311828","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR121","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J et\u00a0al (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22:443\u2013452","journal-title":"Int Immunol"},{"key":"8_CR122","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00296-009-1249-0","volume":"31","author":"G Wang","year":"2011","unstructured":"Wang G, Hu P, Yang J, Shen G, Wu X (2011) The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int 31:513\u2013519","journal-title":"Rheumatol Int"},{"key":"8_CR123","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985\u2013988","journal-title":"Science"},{"key":"8_CR124","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271\u2013275","journal-title":"Science"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.it.2011.06.002","volume":"32","author":"K Wing","year":"2011","unstructured":"Wing K, Yamaguchi T, Sakaguchi S (2011) Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 32:428\u2013433","journal-title":"Trends Immunol"},{"key":"8_CR126","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917\u2013927","journal-title":"Cancer Res"},{"key":"8_CR127","first-page":"41","volume":"80","author":"T Yanagawa","year":"1995","unstructured":"Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ (1995) CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population. J Clin Endocrinol Metab 80:41\u201345","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR128","first-page":"13","volume":"29","author":"Q Yang","year":"2011","unstructured":"Yang Q, Liu Y, Liu D, Zhang Y, Mu K (2011) Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population. Clin Exp Rheumatol 29:13\u201318","journal-title":"Clin Exp Rheumatol"},{"key":"8_CR129","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/jpet.115.227249","volume":"355","author":"Z Yang","year":"2015","unstructured":"Yang Z et al (2015) Integrated pharmacokinetic\/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-CD28 receptor antagonist BMS-931699. J Pharmacol Exp Ther 355:506\u2013515","journal-title":"J Pharmacol Exp Ther"},{"key":"8_CR130","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T (2012) Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209:1201\u20131217","journal-title":"J Exp Med"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1073\/pnas.0710951105","volume":"105","author":"T Yoshida","year":"2008","unstructured":"Yoshida T, Jiang F, Honjo T, Okazaki T (2008) PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci U S A 105:3533\u20133538","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR132","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature20105","volume":"539","author":"Y Yu","year":"2016","unstructured":"Yu Y et al (2016) Single-cell RNA-seq identifies a PD-1(hi) ILC progenitor and defines its development pathway. Nature 539:102\u2013106","journal-title":"Nature"},{"key":"8_CR133","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10815-014-0371-4","volume":"32","author":"MR Zamani","year":"2015","unstructured":"Zamani MR, Asbagh FA, Massoud AH, Salmaninejad A, Massoud A, Rezaei N (2015) Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men. J Assist Reprod Genet 32:103\u2013106","journal-title":"J Assist Reprod Genet"},{"key":"8_CR134","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","volume":"44","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Vignali DA (2016) Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity 44:1034\u20131051","journal-title":"Immunity"},{"key":"8_CR135","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/eji.200737461","volume":"37","author":"X Zhong","year":"2007","unstructured":"Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL (2007) PD-L2 expression extends beyond dendritic cells\/macrophages to B1 cells enriched for V(H)11\/V(H)12 and phosphatidylcholine binding. Eur J Immunol 37:2405\u20132410","journal-title":"Eur J Immunol"},{"key":"8_CR136","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.4049\/jimmunol.176.6.3480","volume":"176","author":"B Zhu","year":"2006","unstructured":"Zhu B et al (2006) Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 176:3480\u20133489","journal-title":"J Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Co-signal Molecules in T Cell Activation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-32-9717-3_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T14:53:17Z","timestamp":1722091997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-32-9717-3_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9789813297166","9789813297173"],"references-count":138,"URL":"https:\/\/doi.org\/10.1007\/978-981-32-9717-3_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"23 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}